2019
DOI: 10.1155/2019/4189275
|View full text |Cite
|
Sign up to set email alerts
|

Acute Myeloid Leukemia Presenting as Myeloid Sarcoma with a Predisposition to the Gynecologic Tract

Abstract: Myeloid sarcoma (MS) is a rare, extramedullary tumor consisting of immature white blood cells of myeloid lineage. MS is usually associated with the concurrent diagnosis of acute myeloid leukemia (AML) but can also present in the absence of bone marrow disease or at relapse of AML. MS of the gynecologic tract is exceedingly rare; however, it is hypothesized that it is likely more prevalent than previously understood given postmortem findings and persistence in preserved ovarian tissue. There is minimal literatu… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
11
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 10 publications
(11 citation statements)
references
References 16 publications
0
11
0
Order By: Relevance
“…In our case, it was located in the left ovary. The tumor diameter ranged from microscopic size to 25 cm (25,28). The size of the tumor in our case was 9x8.5 cm.…”
Section: Discussionmentioning
confidence: 63%
See 3 more Smart Citations
“…In our case, it was located in the left ovary. The tumor diameter ranged from microscopic size to 25 cm (25,28). The size of the tumor in our case was 9x8.5 cm.…”
Section: Discussionmentioning
confidence: 63%
“…The patient ages in the case reports ranged from 3 months to 58 years. The mean age of the patients was 32.1 years (18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33). Most of the patients were in the reproductive age.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Myeloid sarcoma (MS) describes a tumour mass consisting of myeloid blasts occurring at an anatomical site out with the bone marrow (BM). It can occur in isolation or precede the onset of leukaemia and is described as non-leukaemic MS in such cases ( Kahn et al, 2019 ). It is important to note that almost half of all patients with non-leukaemic MS will develop acute leukaemia with reported interval rates of 5–11 months ( Yamauchi and Yasuda, 2002 ).…”
Section: Discussionmentioning
confidence: 99%